Ixia (Olmesartan Medoxomil)

• Olmesartan Medoxomil is used to treat conditions within the hypertension disease family, helping to control elevated arterial pressure.
• Essential hypertension: reduces systolic and diastolic blood pressure, improving long‑term cardiovascular risk management.
• Renal hypertension: lowers blood pressure in patients with hypertension secondary to renal disease, supporting kidney function preservation.
• Hypertension with left ventricular hypertrophy: helps regress cardiac remodeling by maintaining optimal blood pressure levels.

• Olmesartan Medoxomil selectively blocks angiotensin II type 1 (AT1) receptors on vascular smooth muscle and adrenal cells, preventing angiotensin II‑mediated vasoconstriction and aldosterone release. This inhibition leads to vasodilation, reduced sodium and water retention, and ultimately a decrease in systemic blood pressure.

Common Side Effects

• Dizziness: sensation of light‑headedness, especially after standing.
• Headache: mild to moderate pain often occurring early in therapy.
• Fatigue: general feeling of tiredness without exertion.
• Nausea: upset stomach, sometimes with mild vomiting.
• Upper respiratory tract infection: transient cold‑like symptoms.
• Back pain: occasional muscular discomfort.

Serious or Rare Side Effects

• Angioedema: swelling of face, lips, tongue, or throat requiring immediate medical attention.
• Hyperkalemia: elevated blood potassium that can cause cardiac rhythm disturbances.
• Acute kidney injury: sudden decline in renal function, indicated by reduced urine output or increased creatinine.
• Severe hypotension: marked drop in blood pressure leading to fainting or shock.
• Hepatic injury: abnormal liver enzymes or jaundice indicating liver stress.

Before initiating therapy, consider the following precautions:

• Blood pressure monitoring: regularly check to ensure therapeutic targets are met.
• Renal function assessment: evaluate serum creatinine and eGFR, especially in patients with pre‑existing kidney disease.
• Electrolyte balance: monitor potassium levels to avoid hyperkalemia.
• Hepatic impairment: use caution in patients with moderate to severe liver disease.
• Pregnancy and lactation: discuss potential risks with a healthcare professional before use.
• Store at ambient temperature: keep below 25 °C, retain in original packaging, and protect from moisture.

Olmesartan Medoxomil may interact with several medicines. Review the following categories:

Major Interactions (Avoid)

• Aliskiren (in diabetic patients): combined use can increase risk of renal dysfunction and hyperkalemia.
• Potassium‑sparing diuretics or supplements: may cause dangerous elevations in serum potassium.
• ACE inhibitors: concurrent use raises the likelihood of angioedema and hyperkalemia.

Moderate Interactions (Monitor Closely)

• Thiazide diuretics: may enhance antihypertensive effect, requiring blood pressure monitoring.
• NSAIDs (e.g., ibuprofen): can attenuate the blood‑pressure‑lowering action and affect renal function.